2022
DOI: 10.1016/j.aace.2021.10.005
|View full text |Cite
|
Sign up to set email alerts
|

Two Cases of Methimazole-Induced Agranulocytosis With Their Risk Factors

Abstract: Background: Antithyroid drugs, such as methimazole (MMI), are standard therapies for the medical management of thyrotoxicosis. Agranulocytosis is a rare but lethal adverse effect of antithyroid medications. We have reported 2 cases of MMI-induced agranulocytosis with similar risk factors that likely predisposed them to this adverse reaction. Case Report: Case 1 involved a 71-year-old woman, with a history of Graves disease, who presented with an altered mental status. She was recently discharged on 40 mg of MM… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 9 publications
0
1
0
Order By: Relevance
“… 4 In another case, authors also discussed potential risk factors associated with the rare but serious side effect of methimazole, agranulocytosis, in patients with Graves disease. 5 …”
mentioning
confidence: 99%
“… 4 In another case, authors also discussed potential risk factors associated with the rare but serious side effect of methimazole, agranulocytosis, in patients with Graves disease. 5 …”
mentioning
confidence: 99%